ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2459

Nivolumab-Induced Synovial Tissue T Cell Infiltration, Sustained PD1 Occupancy and Resolution of Severe Synovitis with Infliximab Therapy

William Murray-Brown1, Helen Weedon1, Tom Wilsdon2, Susanna Proudman3, Jenny Walker1, Malcolm D. Smith4 and Mihir D Wechalekar1,5, 1Rheumatology, Flinders University, Adelaide, Australia, 2Rheumatology, Flinders Medical Centre, Adelaide, Australia, 3Royal Adelaide Hospital, Rheumatology Unit and University of Adelaide, Discipline of Medicine, Adelaide, Australia, 4Rheumotology, Flinders University, Adelaide, Australia, 5Royal Adelaide Hospital, Adelaide, Australia

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: PD-1, rheumatoid arthritis (RA) and synovial cells, synovial fluid

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, October 23, 2018

Title: Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster III: Complications of Therapy, Outcomes, and Measures

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Checkpoint inhibitors (CI) for cancer therapy are associated with inflammation that can recapitulate features of autoimmunity, including synovitis resembling rheumatoid arthritis (RA). No reports have investigated cellular infiltrates in the synovial tissue (ST) of these patients and no guidelines exist to manage them. Thus, we provide the first report on ST cellular infiltration in PD1 inhibitor-induced rheumatic immune-related adverse-events (irAE).

Methods:

ST biopsies, synovial fluid (SF) and PBMCs from a nivolumab-treated small cell lung cancer (SCLC) patient with severe peripheral inflammatory polyarthritis and inadequate response to DMARDs (negative RF and ACPA); 3 DMARD-naïve patients with seropositive early RA were used as comparators.

Serial sections from fresh-frozen ST blocks were stained with H&E, CD3, CD45RO, CD55 and CD68 and semi-quantitatively scored. ST, SF and PBMC single cell suspensions were stained with Zombie UV®, CD45RO, PD1, CD3, ICOS, CD8, CD4 CD20 prior to flow cytometric acquisition.

Results: CD68+ macrophage, CD20+ B cell and CD3+ T cell and CD45RO+ memory T cell infiltration in irAE was comparable to RA ST on semi-quantitative scoring, while TNFα staining was markedly elevated in irAE compared to RA (irAE-TNFα; 4, RA-TNFα; 2) (Figure 1). Flow cytometric analysis identified persistent CD45RO_ memory T cell infiltration in the ST and SF compartments (irAE: ST; 27.7, SF; 24.9) compared to RA (RA: ST mean and SEM; 27.5±3.63: SF; 35.9±4.85: n=3 for each), driven by continued occupancy of PD1 by nivolumab even 200-days after cessation of treatment (Figure 2). Finally, treatment with infliximab resulted in partial remission of symptoms and reduced synovitis

Figure 1. A, RA ST sections (images representative of all 3 RA). B, ICI-irAE SCLC ST sections. Images were captured at x10 magnification.

Figure 2. T-Sne global analysis performed on all samples concatenated in a common dimensionally reduced space. Comparable CD45RO+ T cell frequency in ST (irAE; 27.7, RA mean and SEM;26.5±2.3, n=3) and SF (irAE;24.9, RA; 36.6±1.79, n=3), flow cytometry revealed a distinct absence of PD1 staining in irAE (ST: irAE: 0.18, SF; 0.20, PBMCs; 0.46) compared to RA (RA: ST; 12.13±1.63: SF; 25.95±2.85: PBMCs; 0.11±0.13, n=3). RA plots representative of all samples.

Conclusion:

ST infiltration in irAE SCLC recapitulates many features of RA histopathology. The continued persistence of nivolumab occupancy in rheumatic-irAEs provides a mechanism for exacerbated inflammation. Infliximab treatment was shown to lead to remission in irAE demonstrating high levels of ST TNFα.


Disclosure: W. Murray-Brown, None; H. Weedon, None; T. Wilsdon, None; S. Proudman, None; J. Walker, None; M. D. Smith, None; M. D. Wechalekar, None.

To cite this abstract in AMA style:

Murray-Brown W, Weedon H, Wilsdon T, Proudman S, Walker J, Smith MD, Wechalekar MD. Nivolumab-Induced Synovial Tissue T Cell Infiltration, Sustained PD1 Occupancy and Resolution of Severe Synovitis with Infliximab Therapy [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/nivolumab-induced-synovial-tissue-t-cell-infiltration-sustained-pd1-occupancy-and-resolution-of-severe-synovitis-with-infliximab-therapy/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/nivolumab-induced-synovial-tissue-t-cell-infiltration-sustained-pd1-occupancy-and-resolution-of-severe-synovitis-with-infliximab-therapy/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology